<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114517</url>
  </required_header>
  <id_info>
    <org_study_id>AG0025</org_study_id>
    <secondary_id>R01AG024154</secondary_id>
    <nct_id>NCT00114517</nct_id>
  </id_info>
  <brief_title>ELITE: Early Versus Late Intervention Trial With Estradiol</brief_title>
  <official_title>Biologic Response of Menopausal Women to 17B-Estradiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the
      progression of early (subclinical) atherosclerosis and cognitive decline in healthy
      postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis to be tested is that 17B-estradiol (estrogen) will reduce the
      progression of early atherosclerosis if initiated soon after menopause when the vascular
      endothelium (lining of blood vessels) is relatively healthy versus later when the endothelium
      has lost its responsiveness to estrogen. Ultrasonography will be used to measure the rate of
      change in the thickness of the carotid artery and cardiac computed tomography (CT) will be
      used to measure coronary artery calcium and coronary artery lesions. The second hypothesis to
      be tested is that 17B-estradiol (estrogen) will reduce the progression of cognitive decline
      if initiated soon after menopause when healthy brain tissue remains responsive to estrogen
      versus later when brain tissue has lost its responsiveness to estrogen.

      A total of 643 (actual)(504, initially proposed) postmenopausal women were randomized
      according to their number of years since menopause, less than 6 years or 10 years or more, to
      receive either oral 17B-estradiol 1 mg daily or a placebo. Women with a uterus will also use
      vaginal progesterone gel 4% (or a placebo gel) the last ten days of each month. The vaginal
      progesterone will be distributed in a double-blind fashion along with the randomized
      treatment so that only women exposed to active treatment will receive active progesterone. As
      initially proposed, participants will undergo ultrasonography at baseline and every 6 months
      throughout the 2 to 5 years (average 3 years) of randomized treatment. Participants will also
      undergo cognitive testing at baseline and after 3 years of randomized treatment. The trial
      has been extended for an additional 2 to 2.5 years of randomized treatment (overall average
      randomized treatment of 5 years and range of 2 to 8.5 years). Ultrasonography will continue
      to be collected every 6 months and upon completion of randomized treatment, participants will
      undergo cardiac CT for coronary artery calcium and coronary artery lesion measurements.
      Participants will also undergo a third cognitive testing at the completion of randomized
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 5, 2013</completion_date>
  <primary_completion_date type="Actual">February 12, 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Change of Distal Common Carotid Artery (CCA) Far Wall Intima-media Thickness (IMT)</measure>
    <time_frame>Twice at baseline and then every 6 months on trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Neurocognitive Function (Global Cognition)</measure>
    <time_frame>Baseline and at 2.5 years and 5 years</time_frame>
    <description>All neuropsychological test scores at baseline and follow-up assessments were standardized ([raw score - mean score]/standard deviation) using the baseline means and standard deviations from the entire ELITE sample. Each of three cognitive composite scores was calculated at baseline and follow-up assessments as the weighted average of the individual donor standardized test scores, weighted by the inverse correlation among tests.The change from baseline (endpoint minus baseline cognitive outcome) was computed for each of the cognitive scores (verbal memory, global cognition, and executive functions). Since the outcome is not a single test but a weighted average of multiple tests, the range is not standard and not reported. Higher scores mean better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Coronary Artery Calcium Measured by Cardiac Computed Tomography</measure>
    <time_frame>End of randomized treatment</time_frame>
    <description>measurement of coronary artery calcium at end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>17B-estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral 17B-estradiol 1 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo oral 17B-estradiol daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral 17B-estradiol</intervention_name>
    <description>Oral 17B-estradiol 1 mg daily</description>
    <arm_group_label>17B-estradiol</arm_group_label>
    <other_name>Estrace</other_name>
    <other_name>Estrogen replacement therapy</other_name>
    <other_name>Estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo oral 17B-estradiol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a serum estradiol level 25 pg/ml or less

          -  No period for 6 months or more

          -  Postmenopausal less than 6 years, OR 10 years or longer

        Exclusion Criteria:

          -  Clinical signs, symptoms, or personal history of cardiovascular disease

          -  Women who have had a hysterectomy only and no oophorectomy (since time from menopause
             cannot be determined)

          -  Diabetes mellitus or fasting serum glucose 140 mg/dL or greater

          -  Uncontrolled hypertension (diastolic blood pressure 110 mmHg or greater)

          -  Thyroid disease (untreated)

          -  Serum creatinine greater than 2.0 mg/dL

          -  Plasma triglyceride levels greater than 500 mg/dL

          -  Life threatening disease with prognosis less than 5 years

          -  Cirrhosis or liver disease

          -  History of deep vein thrombosis or pulmonary embolism

          -  History of breast cancer

          -  Current hormone replacement therapy (HRT)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard N. Hodis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2005</study_first_submitted>
  <study_first_submitted_qc>June 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2005</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>June 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2017</results_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Howard Hodis</investigator_full_name>
    <investigator_title>Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Professor of Medicine and Preventive Medicine, Professor of Molecular Pharmacology and Toxicology, Director, Atherosclerosis Research Unit</investigator_title>
  </responsible_party>
  <keyword>atherosclerosis</keyword>
  <keyword>CAD</keyword>
  <keyword>cardiac computed tomography</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>carotid artery intima-media thickness</keyword>
  <keyword>cognitive function</keyword>
  <keyword>computed tomography</keyword>
  <keyword>coronary artery calcium</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>coronary artery lesions</keyword>
  <keyword>CVD</keyword>
  <keyword>estrogen</keyword>
  <keyword>estrogen therapy</keyword>
  <keyword>hormone therapy</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>subclinical vascular disease</keyword>
  <keyword>timing hypothesis</keyword>
  <keyword>ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Postmenopause 17B-estradiol</title>
          <description>Early postmenopause, &lt;6 years-since-menopause oral 17B-estradiol 1 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Early Postmenopause Placebo</title>
          <description>Early postmenopause &lt;6 years-since-menopause</description>
        </group>
        <group group_id="P3">
          <title>Late Postmenopause 17B-estradiol</title>
          <description>Late postmenopause &gt;10 years-since-menopause oral 17B-estradiol 1 mg daily</description>
        </group>
        <group group_id="P4">
          <title>Late Postmenopause Placebo</title>
          <description>Late postmenopause &gt;10 years-since-menopause</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="172"/>
                <participants group_id="P4" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Postmenopause 17B-estradiol</title>
        </group>
        <group group_id="B2">
          <title>Early Postmenopause Placebo</title>
        </group>
        <group group_id="B3">
          <title>Late Postmenopause 17B-estradiol</title>
        </group>
        <group group_id="B4">
          <title>Late Postmenopause Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="172"/>
            <count group_id="B4" value="176"/>
            <count group_id="B5" value="596"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" lower_limit="53.2" upper_limit="57.9"/>
                    <measurement group_id="B2" value="55.4" lower_limit="52.5" upper_limit="57.8"/>
                    <measurement group_id="B3" value="64.3" lower_limit="60.5" upper_limit="68.6"/>
                    <measurement group_id="B4" value="63.0" lower_limit="59.9" upper_limit="67.0"/>
                    <measurement group_id="B5" value="60.0" lower_limit="55.5" upper_limit="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="596"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change of Distal Common Carotid Artery (CCA) Far Wall Intima-media Thickness (IMT)</title>
        <time_frame>Twice at baseline and then every 6 months on trial</time_frame>
        <population>Early postmenopause group (&lt;6 years since menopause) at baseline and late postmenopause group (&gt;10 years since menopause) at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>17B-estradiol</title>
            <description>Oral 17B-estradiol 1 mg daily
Oral 17B-estradiol: Oral 17B-estradiol 1 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo oral 17B-estradiol daily
Placebo: Matched placebo oral 17B-estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change of Distal Common Carotid Artery (CCA) Far Wall Intima-media Thickness (IMT)</title>
          <population>Early postmenopause group (&lt;6 years since menopause) at baseline and late postmenopause group (&gt;10 years since menopause) at baseline.</population>
          <units>mm per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early postmenopause group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0044" lower_limit="0.0026" upper_limit="0.0061"/>
                    <measurement group_id="O2" value="0.0078" lower_limit="0.0060" upper_limit="0.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late postmenopause group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0100" lower_limit="0.0085" upper_limit="0.0115"/>
                    <measurement group_id="O2" value="0.0088" lower_limit="0.0073" upper_limit="0.0103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurocognitive Function (Global Cognition)</title>
        <description>All neuropsychological test scores at baseline and follow-up assessments were standardized ([raw score – mean score]/standard deviation) using the baseline means and standard deviations from the entire ELITE sample. Each of three cognitive composite scores was calculated at baseline and follow-up assessments as the weighted average of the individual donor standardized test scores, weighted by the inverse correlation among tests.The change from baseline (endpoint minus baseline cognitive outcome) was computed for each of the cognitive scores (verbal memory, global cognition, and executive functions). Since the outcome is not a single test but a weighted average of multiple tests, the range is not standard and not reported. Higher scores mean better outcomes.</description>
        <time_frame>Baseline and at 2.5 years and 5 years</time_frame>
        <population>Early postmenopause group (&lt;6 years since menopause) at baseline and late postmenopause group (&gt;10 years since menopause) at baseline. Sample size represents the number of participants with analyzable data collected at baseline, 2.5 years and 5.0 years.</population>
        <group_list>
          <group group_id="O1">
            <title>17B-estradiol</title>
            <description>Oral 17B-estradiol 1 mg daily
Oral 17B-estradiol: Oral 17B-estradiol 1 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo oral 17B-estradiol daily
Placebo: Matched placebo oral 17B-estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurocognitive Function (Global Cognition)</title>
          <description>All neuropsychological test scores at baseline and follow-up assessments were standardized ([raw score – mean score]/standard deviation) using the baseline means and standard deviations from the entire ELITE sample. Each of three cognitive composite scores was calculated at baseline and follow-up assessments as the weighted average of the individual donor standardized test scores, weighted by the inverse correlation among tests.The change from baseline (endpoint minus baseline cognitive outcome) was computed for each of the cognitive scores (verbal memory, global cognition, and executive functions). Since the outcome is not a single test but a weighted average of multiple tests, the range is not standard and not reported. Higher scores mean better outcomes.</description>
          <population>Early postmenopause group (&lt;6 years since menopause) at baseline and late postmenopause group (&gt;10 years since menopause) at baseline. Sample size represents the number of participants with analyzable data collected at baseline, 2.5 years and 5.0 years.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early postmenopause group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.11" upper_limit="0.73"/>
                    <measurement group_id="O2" value="0.40" lower_limit="-0.07" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late postmenopause group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.14" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.20" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Coronary Artery Calcium Measured by Cardiac Computed Tomography</title>
        <description>measurement of coronary artery calcium at end of study</description>
        <time_frame>End of randomized treatment</time_frame>
        <population>CAC data was obtained in 380 participants. Participants who were not taking the study agents at the last follow-up visit, who had adherence to the study regimen that was lower than 80% or who had a CAC scan more than 6 months after the final study visit were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>17B-estradiol</title>
            <description>Oral 17B-estradiol 1 mg daily
Oral 17B-estradiol: Oral 17B-estradiol 1 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched placebo oral 17B-estradiol daily
Placebo: Matched placebo oral 17B-estradiol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Coronary Artery Calcium Measured by Cardiac Computed Tomography</title>
          <description>measurement of coronary artery calcium at end of study</description>
          <population>CAC data was obtained in 380 participants. Participants who were not taking the study agents at the last follow-up visit, who had adherence to the study regimen that was lower than 80% or who had a CAC scan more than 6 months after the final study visit were not included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Early postmenopause group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Late postmenopause gorup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events collected per intervention</desc>
      <group_list>
        <group group_id="E1">
          <title>17B-estradiol</title>
          <description>Oral 17B-estradiol 1 mg daily
Oral 17B-estradiol: Oral 17B-estradiol 1 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matched placebo oral 17B-estradiol daily
Placebo: Matched placebo oral 17B-estradiol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>aplastic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>unstable angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pleuropericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>veritgo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ischemic colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>illeitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>ulcerative colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>breast cancer in situ</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>colorectal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>mycosis fungoides</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>polycythemia vera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>uterine cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="323"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="323"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>drug hypersensitivity</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="323"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="323"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="323"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="323"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="323"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="323"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="323"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cervical dysplasia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="323"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="323"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="320"/>
              </event>
              <event>
                <sub_title>vulvovaginal pruritis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="323"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="320"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard N. Hodis, M.D., Director, Atherosclerosis Research Unit</name_or_title>
      <organization>University of Southern California</organization>
      <phone>323 442 1478</phone>
      <email>athero@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

